Nasal decongestants in the treatment of nasal obstruction

Nasal congestion is one of the most common symptoms of common colds and rhinitis, due to an inflammatory reaction, vasodilation, increased nasal blood flow and vascular permeability. Nasal obstruction is often a multifactorial problem, in addition to infectious causes, it can be caused by a combination of anatomical aberrations, swelling of the nasal mucosa and enlargement of the turbinates. Anatomical and structural problems, such as nasal septum deviation and nasal valve collapse, are usually treated surgically. Drug therapy of nasal obstruction is aimed at reducing edema and inflammation of the nasal mucosa. Pharmacotherapy of nasal obstruction is aimed at reducing inflammation and/or swelling of the mucous membrane. Decongestants are widely prescribed to relieve symptoms. The drugs used have different mechanisms of action and include systemic and topical drugs. This article discusses decongestants as a treatment for nasal obstruction. When applied topically, the drugs of this group act directly on the α2 and α1-adrenergic receptors of the nasal cavity, causing vasoconstriction, a decrease in the volume of the nasal conch, an increase in nasal patency, and relieving the symptoms of obstruction. The existing risk of developing side effects, both systemic and local, is reduced with atopic exposure and proper dosing of the drug used. Preferably, the use of drugs with low bioavailability. The suppression of the ciliated epithelium can be caused not only by the pathological process, but also by the composition of drugs. The value is given to the acidity of the buffer system. The optimal pH value of intranasal agents is about 6 (neutral range). The combination with anticholinesterase substances reduces the production of pathological discharge. The use of multi-component medicines allows you to restore nasal breathing and suppress excessive nasal secretion. One of the effective and safe drugs of topical action is Xylometazoline, as a monocomponent agent or in combination with ipratropium bromide.

1. Mösges R., Shah-Hosseini K., Hucke H.P., Joisten M.J. Dexpanthenol: An Overview of its Contribution to Symptom Relief in Acute Rhinitis Treated with Decongestant Nasal Sprays. Adv Ther. 2017;34(8):1850–1858. doi: 10.1007/s12325-017-0581-0.

2. Beard S. Rhinitis. Prim Care. 2014;41(1):33–46. doi: 10.1016/j.pop.2013.10.005.

3. Deckx L., De Sutter A.I., Guo L., Mir N.A., van Driel M.L. Nasal Decongestants in Monotherapy for the Common Cold. Cochrane Database Syst Rev. 2016;10(10):CD009612. doi: 10.1002/14651858.CD009612.pub2.

4. Shaikh N., Wald E.R., Pi M. Decongestants, Antihistamines and Nasal Irrigation for Acute Sinusitis in Children. Cochrane Database Syst Rev. 2010;(12):CD007909. doi: 10.1002/14651858.CD007909.pub2.

5. Keustermans W., Huysmans T., Danckaers F., Zarowski A., Schmelzer B., Sijbers J., Dirckx J.J.J. High Quality Statistical Shape Modelling of the Human Nasal Cavity and Applications. R Soc Open Sci. 2018;5(12):181558. doi: 10.1098/rsos.181558.

6. Sur D.K.C., Plesa M.L. Chronic Nonallergic Rhinitis. Am Fam Physician. 2018;98(3): 171–176. Available at: https://aafp.org/afp/2018/0801/p171.html.

7. Fokkens W.J., Lund V.J., Hopkins C., Hellings P.W., Kern R., Reitsma S. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(S29 Suppl.):1–464. doi: 10.4193/Rhin20.600.

8. Papadopoulos N.G., Guibas G.V. Rhinitis Subtypes, Endotypes, and Definitions. Immunol Allergy Clin North Am. 2016;36(2):215–233. doi: 10.1016/j.iac.2015.12.001.

9. Casale M., Moffa A., Cassano M., Carinci F., Lopez M.A., Trecca E.M.C. et al. Saline Nasal Irrigations for Chronic Rhinosinusitis: From Everyday Practice to Evidence-Based Medicine. An Update. Int J Immunopathol Pharmacol. 2018;32:2058738418802676. doi: 10.1177/2058738418802676.

10. Papadopoulos N.G., Guibas G.V. Rhinitis Subtypes, Endotypes, and Definitions. Immunol Allergy Clin North Am. 2016;36(2):215–233. doi: 10.1016/j.iac.2015.12.001.

11. Hermelingmeier K.E., Weber R.K., Hellmich M., Heubach C.P., Mösges R. Nasal Irrigation as an Adjunctive Treatment in Allergic Rhinitis: A Systematic Review and Meta-Analysis. Am J Rhinol Allergy. 2012;26(5):e119–e125. doi: 10.2500/ajra.2012.26.3787.

12. Wise S.K., Lin S.Y., Toskala E., Orlandi R.R., Akdis C.A., Alt J.A. et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. doi: 10.1002/alr.22073.

13. Ryazantsev S.V., Goncharov O.I. Allergic Rhinitis. Meditsinskiy sovet = Medical Council. 2018;(20):76–79. (In Russ.) doi: 10.21518/2079-701X2018-20-76-79.

14. Settipane R.A., Kaliner M.A. Chapter 14: Nonallergic Rhinitis. Am J Rhinol Allergy. 2013;27(1 Suppl.):S48–S51. doi: 10.2500/ajra.2013.27.3927.

15. Karpishchenko S.A., Vereshchagina O.E., Baranskaya S.V., Karpov A.A Minimally Invasive Maxillary Sinus Approach: Postop Aspects. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2018;24(2):4–12. (In Russ.) Available at: https://foliaopr.spb.ru/wp-content/uploads/2018/02/Folia_24_2_2018.pdf.

16. Karpishchenko S.A., Baranskaya S.V. Treatment options of the nasal cavity and paranasal sinuses diseases. Meditsinskiy sovet = Medical Council. 2019;(17):107–111. (In Russ.) doi: 10.21518/2079-701X-2019-17-107-111.

17. Karpischenko S.A., Kolesnikova O.M. Rhinorrhea: Symptom of Many Diseases! Meditsinskiy sovet = Medical Council. 2017;(20):68–71. (In Russ.) doi: 10.21518/2079-701X-2017-20-68-71.

18. Karpishchenko S.A., Vereshchagina O.E., Teplova E.О. Clinical Approach to the Selection of Topical Decongestants in Paediatric Otolaryngology Practice. Meditsinskiy sovet = Medical Council. 2019;(2):168–172. (In Russ.) doi: 10.21518/2079-701X-2019-2-168-172.

19. Kryukov A.I., Turovskiy A.B., Kolbanova I.G., Musayev K.M., Karasov A.B. Rhinitis Medicamentosa – Preventable Disease. Meditsinskiy sovet = Medical Council. 2019;(20):27–30. (In Russ.) doi: 10.21518/2079-701X2019-20-27-30.

20. Eccles R., Martensson K., Chen S.C. Effects of Intranasal Xylometazoline, Alone or in Combination with Ipratropium, in Patients with Common Cold. Curr Med Res Opin. 2010;26(4):889–899. doi: 10.1185/03007991003648015.

21. Taverner D., Latte J. Nasal Decongestants for the Common Cold. Cochrane Database Syst Rev. 2007;(1):CD001953. doi: 10.1002/14651858.CD001953.pub3.

22. Deckx L., De Sutter A.I., Guo L., Mir N.A., van Driel M.L. Nasal Decongestants in Monotherapy for the Common Cold. Cochrane Database Syst Rev. 2016;10(10):CD009612. doi: 10.1002/14651858.CD009612.pub2.